• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23378 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2003     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for rheumatoid arthritis - horizon scanning review
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rituximab (MabThera®)
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia
2009     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (Rituxan/MabThera) for the first- and second-line treatment of chronic lymphocytic leukaemia
2002     NIHR Health Technology Assessment programme Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Rituximab biosimilars
2004     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab for 1st line low-grade non-Hodgkin's lymphoma - horizon scanning review
2002     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab for aggressive B-cell lymphoma - horizon scanning review
2003     National Institute for Clinical Excellence (NICE) Rituximab for aggressive non-Hodgkin's lymphoma
2003     Quality Improvement Scotland (NHS QIS ) Rituximab for aggressive non-Hodgkin's lymphoma
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical and cost-effectiveness
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for non-hodgkin's lymphoma: a review of the clinical and cost- effectiveness and guidelines
2006     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for rheumatoid arthritis
2010     NIHR Health Technology Assessment programme Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
2011     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma. NICE technology appraisal guidance 226
2009     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of chronic lymphocytic leukaemia
2012     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of stage III-IV follicular lymphoma. NICE technology appraisal guidance 243
2012     NIHR Health Technology Assessment programme Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation
2009     NIHR Health Technology Assessment programme Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
2006     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of follicular lymphoma
2006     Quality Improvement Scotland (NHS QIS ) Rituximab for the treatment of follicular lymphoma
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for the treatment of primary membranous nephropathy
2010     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
2009     NIHR Health Technology Assessment programme Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2008     Quality Improvement Scotland (NHS QIS ) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2008     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37)
2010     NIHR Health Technology Assessment programme Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
2009     NIHR Health Technology Assessment programme Rituximab for the treatment of rheumatoid arthritis
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Rituximab for the treatment of rheumatoid arthritis
2008     Institute for Clinical Effectiveness and Health Policy (IECS) Rituximab for the treatment of rheumatoid arthritis
2007     Quality Improvement Scotland (NHS QIS ) Rituximab for the treatment of rheumatoid arthritis
2007     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of rheumatoid arthritis (replaced by TA195)
2021     Agency for Care Effectiveness (ACE) Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
2002     Blue Cross Blue Shield Association (BCBS) Rituximab for treatment of intermediate and aggressive B-cell non-Hodgkin's lymphomas
2013     NIHR Health Technology Assessment programme Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
2014     National Institute for Health and Care Excellence (NICE) Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. NICE technology appraisal guidance 308
2007     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Bay 59-7939) for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery: horizon scanning technology briefing
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism
2011     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for acute coronary syndrome
2010     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for prevention of venous thromboembolism in medically ill patients
2009     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for stroke prevention in atrial fibrillation
2010     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for venous thromboembolism
2015     National Institute for Health and Care Excellence (NICE) Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. NICE technology appraisal guidance 335
2019     National Institute for Health and Care Excellence (NICE) Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. NICE technology appraisal guidance 607
2011     NIHR Health Technology Assessment programme Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation: a single technology appraisal
2012     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE technology appraisal guidance 256
2009     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
2009     NIHR Health Technology Assessment programme Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
2012     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261
2012     NIHR Health Technology Assessment programme Rivaroxaban for the treatment of deep vein thrombosis and secondary prevention of venous thromboembolism
2013     National Institute for Health and Care Excellence (NICE) Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance 287
1998     Wessex Institute for Health Research and Development (WIHRD) Rivastigmine (Exelon TM) in the treatment of senile dementia of the Alzheimer type (SDAT)
2018     Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2010     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Robot-assisted endoscopic thyroidectomy
2022     Agency for Care Effectiveness (ACE) Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2018     National Institute for Health and Care Excellence (NICE) Robot-assisted kidney transplant. NICE interventional procedures guidance 609
2008     Institute for Clinical Effectiveness and Health Policy (IECS) Robot-assisted surgery in prostate cancer
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Robot-assisted surgery in thoracic and visceral indications
2019     European Network for Health Technology Assessment (EUnetHTA) Robot-assisted surgery in thoracic and visceral indications
2023     Austrian Institute for Health Technology Assessment (AIHTA) Robot-assisted surgery in thoracic and visceral indications – Update 2023
2007     Andalusian Health Technology Assessment Area (AETSA) Robot-assisted surgery using da Vinci robot telemanipulation in prostatectomy
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Robot-assisted surgery versus open surgery and laparoscopic surgery: clinical and cost-effectiveness analyses
2009     Belgian Health Care Knowledge Centre (KCE) Robot-assisted surgery: health technology assessment
2008     Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Robot-assisted surgery: the da Vinci robot
2010     Adelaide Health Technology Assessment (AHTA) Robot-assisted therapy for long-term upper limb impairment after stroke
2023     Health Technology Wales (HTW) Robot-assisted thoracic surgery
2020     NIHR Health Technology Assessment programme Robot-assisted training compared with an enhanced upper limb therapy programme and with usual care for upper limb functional limitation after stroke: the RATULS three-group RCT
2024     Penn Medicine Center for Evidence-based Practice (CEP) Robot-assisted vs. laparoscopic surgery for cholecystectomy
2000     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Robotic arm for endoscopic surgery - systematic review, expert panel
2022     Malaysian Health Technology Assessment (MaHTAS) Robotic arm-assisted surgery in total hip arthroplasty, total knee arthroplasty and unicompartmental knee arthroplasty
1999     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Robotic cardiac surgery (systematic review, expert panel)
2012     Medical Services Advisory Committee (MSAC) Robotic image-guided stereotactic precise beam radiosurgery and radiotherapy for prostate and lung
2004     VA Technology Assessment Program (VATAP) Robotic surgery
2002     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Robotic surgery - systematic review, expert panel
2006     VA Technology Assessment Program (VATAP) Robotic surgery - Update 2006
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Robotic surgery versus open-chest surgery for internal mammary artery harvesting and mitral valve surgery: clinical effectiveness
2017     Health Quality Ontario (HQO) Robotic surgical system for radical prostatectomy: a health technology assessment
2017     Health Quality Ontario (HQO) Robotic surgical system for radical prostatectomy: OHTAC recommendation
2023     Ontario Health Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2014     Health Quality Ontario (HQO) Robotic-assisted minimally invasive prostatectomy: OHTAC recommendation
2010     Medical Advisory Secretariat (MAS) Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analaysis
2010     Medical Advisory Secretariat (MAS) Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis
2023     Ontario Health Robotic-assisted partial nephrectomy for kidney cancer
2008     HAYES, Inc. Robotic-assisted prostatectomy
2009     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Robotic-assisted surgery for urological, cardiac and gynaecological procedures
2006     HAYES, Inc. Robotically assisted adrenalectomy (da Vinci Surgical System) (Intuitive Surgical Inc.)
2007     HAYES, Inc. Robotically assisted atrial septal defect repair (da Vinci Surgical System) (Intuitive Surgical Inc.)
2010     HAYES, Inc. Robotically assisted atrial septal defect repair using the da vinci surgical system (Intuitive Surgical Inc.)
2008     HAYES, Inc. Robotically assisted cardiac valve replacement (da Vinci Surgical System) (Intuitive Surgical Inc.)
2004     HAYES, Inc. Robotically assisted coronary artery bypass surgery
2008     HAYES, Inc. Robotically assisted coronary artery bypass surgery
2014     HAYES, Inc. Robotically assisted hysterectomy
2010     HAYES, Inc. Robotically assisted hysterectomy
2008     HAYES, Inc. Robotically assisted hysterectomy (da Vinci Surgical System) (Intuitive Surgical Inc.)
2014     The Regional Health Technology Assessment Centre (HTA-centrum) Robotically assisted laparoscopic surgery for rectal cancer
2007     HAYES, Inc. Robotically assisted mitral valve repair (da Vinci Surgical System) (Intuitive Surgical Inc.)
2013     HAYES, Inc. Robotically assisted mitral valve repair using the da Vinci surgical system (Intuitive Surgical Inc.)
2010     HAYES, Inc. Robotically assisted mitral valve repair using the Da Vinci surgical system (Intuitive Surgical Inc.)
2011     HAYES, Inc. Robotically assisted mitral valve repair using the da Vinci surgical system (Intuitive Surgical Inc.)